A time bomb in cov-lite loans

“Cov-lite loans”, which do not require a borrower to pass financial tests, have proliferated amid the desperate global search for yield.

"It's as if the financial crisis never happened and the lessons from it are ancient history," Jonathan Rochford of Narrow Road Capital told The Daily Telegraph. In the 2000s, toxic subprime mortgages were bundled together in collateralised debt obligations (CDOs) and sold to buyers who didn't realise how much junk the packages actually contained. Ten years later, the surge of covenant-lite loans in the leveraged-loan market could prove to be another "ticking time bomb", says The Daily Telegraph's Tom Rees.

Covenants require a borrowerto pass financial tests. However, "cov-lite loans", which have been stripped of these conditions, have proliferated amid the desperate global search for yield. In the US, cov-lite loans now account for nearly 77% of the estimated $1trn corporate-loan market. And some of these loans are packaged up and resold as CLOs collateralised loan obligations. In the UK, the leveraged loan market hit a record £38bn in 2017 and could grow by 4% this year, according to the Bank of England. Meanwhile the quality of covenants has sunk to a record low, says credit-rating agency Moody's.

Try 6 free issues of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up for MoneyWeek’s free twice-daily newsletter.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Sign up

Marina Gerner is an award-winning journalist and columnist who has written for the Financial Times, the Times Literary Supplement, the Economist, The Guardian and Standpoint magazine in the UK; the New York Observer in the US; and die Bild and Frankfurter Rundschau in Germany.


Marina is also an adjunct professor at the NYU Stern School of Business at their London campus, and has a PhD from the London School of Economics.


Her first book, The Vagina Business, deals with the potential of “femtech” to transform women’s lives, and will be published by Icon Books in September 2024.


Marina is trilingual and lives in London.